www.fdanews.com/articles/74250-transkaryotic-urges-holders-approve-shire-deal
TRANSKARYOTIC URGES HOLDERS APPROVE SHIRE DEAL
July 13, 2005
Transkaryotic Therapies on Tuesday urged shareholders to vote for Shire Pharmaceuticals Group's offer to buy the biotechnology company, or face substantial losses through 2006. The deal with Shire, Britain's third-largest drugmaker, has come under fire from two major holders of Transkaryotic shares, who argue the price of $1.6 billion, or $37 a share, was too low. The rebel investors have said Shire's bid did not fully reflect recent successful trial results of I2S, TKT's experimental treatment for Hunter syndrome, a genetic disorder.